Newsroom
aspergillus-t-10Kx_003 (1)

NEW YORK (May 9, 2017) – TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections.

ECFC

NEW YORK (April 14, 2017) – TGV-inhalonix, a New York-based pharmaceutical company with a consistent track record in developing anti-infective agents, announced they will present data for the research study “Study Of Mul-1867 A Drug Candidate For Inhalation Therapy Of MRSA/VRSA Infections In Patients With Cystic Fibrosis In Murine Lung Infection Model” as an oral presentation at the upcoming 40th European Cystic Fibrosis Conference ( Seville, Spain, 07-10 June 2017).

bts16_banner_1200x600

NEW YORK, NY – 12/8/2016 (PRESS RELEASE JET) –TGV-inhalonix, a New York-based pharmaceutical company with a consistent track record in developing anti-infective agents, announced an upcoming new report on its most advanced novel drug candidate – MUL-1867. The new study results will be presented at The 9th Annual Biotech Showcase Conference in San Francisco, January 9-11 2017.

cff_banner-img

TGV-inhalonix, a New York-based pharmaceutical company with extensive experience developing  novel anti-infective agents, announced that it will present new findings on Mul-1867, its novel drug candidate, the first to have overcome antibiotic resistance of bacterial and fungal pathogens causing lung infections, at the world’s most significant gathering on cystic fibrosis – 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, October 27-29, 2016.

Mul-1867 Novel Drug Candidate Shows Significant Promises Against Rare Pathogens that Cause Life-Threatening Lung Infections In Cystic Fibrosis Patients

BOSTON, June 20, 2016 /PRNewswire/ — A next-generation antibiotic being developed by researchers at the New York-based pharmaceutical company TGV-inhalonix is significantly more effective than traditional drugs in fighting the rise in airway pathogens that cause life-threatening lung infections in cystic fibrosis patients, according to research presented today at ASM Microbe 2016.

TGV-inhalonix Presents Drug Candidate to Treat Mixed Resistant Lung Infections in Cystic Fibrosis

BASEL, SWITZERLAND – 9 June, 2016 – A novel new drug being developed to treat antibiotic-resistant lung infections shows significant promise for treating the often life-threatening mixed bacterial and fungal lung infections contracted by cystic fibrosis patients, according to research presented today by TGV-inhalonix at the 39th European Cystic Fibrosis Conference.

12